cMET: a prognostic marker in papillary renal cell carcinoma?

Erlmeier F, Bruecher B, Stoehr C, Herrmann E, Polifka I, Agaimy A, Trojan L, Ströbel P, Becker F, Wülfing C, Barth P, Stöckle M, Staehler M, Stief C, Haferkamp A, Hohenfellner M, Macher-Göppinger S, Wullich B, Noldus J, Brenner W, Roos FC, Walter B, Otto W, Burger M, Schrader AJ, Hartmann A, Mondorf Y, Ivanyi P, Mikuteit M, Steffens S (2022)

Publication Type: Journal article

Publication year: 2022

Journal

Human Pathology WB Saunders

Book Volume: 121

Pages Range: 1-10

DOI: 10.1016/j.humpath.2021.12.007

Abstract

The tyrosine-protein kinase c-Met plays a decisive role in numerous cellular processes, as a proto-oncogene that supports aggressive tumor behavior. It is still unknown whether c-Met could be relevant for prognosis of papillary RCC (pRCC). Specimen collection was a collaboration of the PANZAR consortium. Patients' medical history and tumor specimens were collected from 197 and 110 patients with type 1 and 2 pRCC, respectively. Expression of cMET was determined by immunohistochemistry. In total, cMET staining was evaluable in of 97 of 197 type 1 and 63 of 110 type 2 pRCC cases. Five-year overall survival revealed no significant difference in dependence of cMET positivity (cMET− vs. cMET+: pRCC type 1: 84.8% vs. 80.3%, respectively [p = 0.303, log-rank]; type 2: 71.4% vs. 64.4%, respectively [p = 0.239, log-rank]). Interestingly, the subgroup analyses showed a significant difference for cMET expression in T stage and metastases of the pRCC type 2 (p = 0.014, p = 0.022, chi-square). The cMET-positive type 2 collective developed more metastases than the cMET-negative cohort (pRCC type 2 M+: cMET−: 2 [4.3%] vs. cMET+: 12 [19%]). cMET expression did not qualify as a prognostic marker in pRCC for overall survival.

Authors with CRIS profile

Franziska Erlmeier Institute of Pathology Iris Polifka Institute of Pathology Abbas Agaimy Lehrstuhl für Allgemeine Pathologie und Pathologische Anatomie Bernd Wullich Lehrstuhl für Urologie Arndt Hartmann Lehrstuhl für Allgemeine Pathologie und Pathologische Anatomie

Involved external institutions

Universitätsklinikum Heidelberg DE Germany (DE) Universitätsmedizin der Johannes Gutenberg-Universität Mainz DE Germany (DE) Klinikum der Universität München DE Germany (DE) Universität Regensburg DE Germany (DE) Universitätsklinikum des Saarlandes (UKS) DE Germany (DE) Universitätsklinikum Münster DE Germany (DE) Universitätsklinikum Göttingen DE Germany (DE) St. Elisabeth Gruppe GmbH - Katholische Kliniken Rhein-Ruhr DE Germany (DE) Johannes Gutenberg-Universität Mainz (JGU) DE Germany (DE) Philipps-Universität Marburg DE Germany (DE) Universitätsklinikum Frankfurt am Main (KGU) DE Germany (DE) Medizinische Hochschule Hannover (MHH) / Hannover Medical School DE Germany (DE)

How to cite

APA:

Erlmeier, F., Bruecher, B., Stoehr, C., Herrmann, E., Polifka, I., Agaimy, A.,... Steffens, S. (2022). cMET: a prognostic marker in papillary renal cell carcinoma? Human Pathology, 121, 1-10. https://doi.org/10.1016/j.humpath.2021.12.007

MLA:

Erlmeier, Franziska, et al. "cMET: a prognostic marker in papillary renal cell carcinoma?" Human Pathology 121 (2022): 1-10.

BibTeX: Download